On the same day The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted that live attenuated influenza vaccine (LAIV), also known as the “nasal spray” flu vaccine, should not be used during the 2016-2017 flu season due to dismal vaccine effectiveness studies, health officials in the United Kingdom said provisional data shows that the Nasal spray flu vaccine has been effective across the pond.
Provisional figures released by Public Health England (PHE) show that the childhood nasal spray flu vaccine has been effective in the UK, both in protecting the children themselves and their communities from flu, prompting health officials to remain confident that the children’s nasal spray flu vaccine plays an important role in protecting children, their families and others in the community from flu during the winter.
The National Institute for Health and Welfare in Finland has confirmed that they saw similar effectiveness levels to the UK in 2015 to 2016 (46% against laboratory confirmed disease), and have confirmed the nasal spray flu vaccine will continue to be used in Finland for the forthcoming winter.
From October 2016, the vaccine will be extended to healthy children in school year 3 in England. Once again, children aged 2, 3 and 4, and in school years 1 and 2 will also be eligible to receive the free vaccine which is quick, effective and painless.
Dr Richard Pebody, head of flu surveillance for PHE said:
We estimate that overall, the vaccine was 57.6% (95% confidence interval: 25.1, 76) effective in preventing influenza infection amongst children in 2015 to 2016. These findings are encouraging and in line with what we also typically see for the adult flu vaccine.
Prior to offering vaccination to all our youngest primary school aged children this season, school age pilots took place in a number of areas across England in 2014 to 2015. In areas where flu vaccine was piloted amongst primary school age children, there was a 94% reduction in GPinfluenza like illness consultation rates, 74% reduction in A&E respiratory attendances and 93% reduction in hospital admissions due to confirmed influenza in primary school children. In the same pilot areas, GP ‘influenza like illness’ consultation rates for adults were 59% lower compared to non-pilot areas.
Flu vaccine is the best protection we have against an unpredictable virus which can cause severe illness and deaths each year not only amongst children but also amongst at-risk groups, including older people, pregnant women and those with an underlying health condition.
Based on intelligence to date, there is no reason to change current recommendations regarding use of the children’s nasal spray vaccine in the UK. We’re delighted that the UK leads the way in offering this vaccine to children and we remain confident that the vaccines used in the Annual Flu Vaccine programme are the most effective that are currently available in protecting both those vaccinated and in reducing transmission of the flu virus in our communities. We will continue to keep the vaccines used in our programmes under review and to take advice from our independent expert scientific committee, the Joint Committee on Vaccination and Immunisations (JCVI).
- Monkeys completely protected from anthrax after vaccination with the anthrax capsule: Research
- Costa Rica approves dengue vaccine, Dengvaxia: 5th country to approve
- Sanofi Pasteur: Four-Strain Influenza Vaccine, VaxigripTetra, gets approval in Europe